In terms of earnings growth today, Pfizer (PFE) is just a middling Big Pharma pick. On a longer-term basis, though, it looks as if the Street is still undervaluing the company's ability to continue to earn strong economic profits and return capital to shareholders. While the near-term news flow has not been great and the company will be hard-pressed to post major earnings growth without a large transaction, there is still value here for the patient shareholder.
Click here for more:
Pfizer's Trade-Off Between Value And Momentum